IE83794B1 - Electrotransport drug delivery - Google Patents
Electrotransport drug delivery Download PDFInfo
- Publication number
- IE83794B1 IE83794B1 IE1999/0566A IE990566A IE83794B1 IE 83794 B1 IE83794 B1 IE 83794B1 IE 1999/0566 A IE1999/0566 A IE 1999/0566A IE 990566 A IE990566 A IE 990566A IE 83794 B1 IE83794 B1 IE 83794B1
- Authority
- IE
- Ireland
- Prior art keywords
- membrane
- agent
- electrode
- flux
- body surface
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title description 13
- 239000012528 membrane Substances 0.000 claims abstract description 182
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 74
- 230000004907 flux Effects 0.000 claims description 48
- 229920005989 resin Polymers 0.000 claims description 30
- 239000011347 resin Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 20
- 229960004503 metoclopramide Drugs 0.000 claims description 20
- 229920002301 cellulose acetate Polymers 0.000 claims description 17
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 17
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 9
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002195 soluble material Substances 0.000 claims description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- 229960002428 fentanyl Drugs 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 239000003456 ion exchange resin Substances 0.000 claims description 4
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 4
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 4
- 229960004739 sufentanil Drugs 0.000 claims description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 3
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 229960000794 baclofen Drugs 0.000 claims description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
- 229940092705 beclomethasone Drugs 0.000 claims description 3
- 229960002537 betamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 3
- 229960004166 diltiazem Drugs 0.000 claims description 3
- 229960001089 dobutamine Drugs 0.000 claims description 3
- 229960001389 doxazosin Drugs 0.000 claims description 3
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims description 3
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000394 droperidol Drugs 0.000 claims description 3
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001142 encainide Drugs 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 3
- 229960000991 ketoprofen Drugs 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 3
- 229960002702 piroxicam Drugs 0.000 claims description 3
- 229960001289 prazosin Drugs 0.000 claims description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960000195 terbutaline Drugs 0.000 claims description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002372 tetracaine Drugs 0.000 claims description 3
- 229960001722 verapamil Drugs 0.000 claims description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 3
- 238000005266 casting Methods 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 238000012360 testing method Methods 0.000 abstract description 11
- 238000000338 in vitro Methods 0.000 abstract description 6
- 239000013543 active substance Substances 0.000 abstract description 2
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 59
- 229940079593 drug Drugs 0.000 description 55
- 238000009792 diffusion process Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 239000011148 porous material Substances 0.000 description 13
- 230000032258 transport Effects 0.000 description 13
- 239000002131 composite material Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- -1 polyethylene Polymers 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000011068 loading method Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 7
- 239000004417 polycarbonate Substances 0.000 description 7
- 229920000515 polycarbonate Polymers 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000001087 glyceryl triacetate Substances 0.000 description 5
- 235000013773 glyceryl triacetate Nutrition 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229960002622 triacetin Drugs 0.000 description 5
- 239000012790 adhesive layer Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920000557 Nafion® Polymers 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005370 electroosmosis Methods 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009057 passive transport Effects 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical class C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 239000003011 anion exchange membrane Substances 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 239000012633 leachable Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010128 melt processing Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000807 solvent casting Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 101100453921 Caenorhabditis elegans kin-29 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 229920013683 Celanese Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229920002821 Modacrylic Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000047703 Nonion Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- IKJFYINYNJYDTA-UHFFFAOYSA-N dibenzothiophene sulfone Chemical group C1=CC=C2S(=O)(=O)C3=CC=CC=C3C2=C1 IKJFYINYNJYDTA-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000012777 electrically insulating material Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002480 polybenzimidazole Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006216 polyvinyl aromatic Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Abstract
ABSTRACT The invention concerns the iontophoretic delivery of active agents, in particular analgesics. A membrane capable of controlling the rate at which an agent is released from an iontophoretic delivery device may be provided. The membrane inhibits agent release from the delivery device when no electrical current is flowing and yet provides minimal impedance to electrically-assisted agent delivery. The membrane is useful both as control membrane in an iontophoretic agent delivery device and as a test membrane for testing the performance characteristics of an iontophoretic agent delivery device in vitro.
Description
ELECTROTRANSPORT DRUG DELIVERY TECHNICAL FIELD This invention relates to a device and method for delivering an agent transdermally or transmucosally by iontophoresis. More particularly, this invention relates to an electrically powered iontophoretic delivery device having a control membrane capable of inhibiting the release of agent from the device when the power is turned off while allowing agent delivery when the power is’turned on.
BACKGROUND ART Iontophoresis, according to Dorland’s Illustrated Medical Dictionary, is defined to be "the introduction, by means of electric current, of ions of soluble salts into the tissues of the body for therapeutic purpose." Iontophoretic devices have been known since the early 1900's. British patent specification No. 410,009 (1934) describes an iontophoretic device which overcame one of the disadvantages of such early devices known to the art at that time, namely the requirement of a special low tension (low voltage) source of current which meant that the patient needed to be immobilized near such source. The device of that British specification was made by forming, from the electrodes and the material containing the medicament or drug to be delivered transdermally, a galvanic cell which itself produced the current necessary for iontophoretically delivering the medicament. This ambulatory device thus permitted iontophoretic drug delivery with substantially less interference with the patient’s daily activities.
More recently, a number of United States patents have issued in the iontophoresis field, indicating a renewed interest in this mode of drug delivery. For example, U.S. Patent No. 3,991,755 issued to Vernon et al; U.S. Patent No. 4,141,359 issued to Jacobsen et al; U.S. Patent No. 4,398,545 issued to Wilson; and U.S. Patent No. 4,250,878 issued to Jacobsen disclose examples of iontophoretic devices and some applications thereof. The iontophoresis process has been found to be useful in the transdermal administration of medicaments or drugs including lidocaine hydrochloride, hydrocortisone, fluoride, penicillin, dexamethasone sodium phosphate, insulin and many other drugs. Perhaps the most common use of iontophoresis is in diagnosing cystic fibrosis by delivering pilocarpine salts iontophoretically. The pilocarpine stimulates sweat production; the sweat is collected and analyzed for its chloride content to detect the presence of the disease.
In presently known iontophoretic devices, at least two electrodes are used. Both of these electrodes are disposed so as to be in intimate electrical contact with some portion of the skin of the body. the electrode from which the ionic substance, medicament, drug One electrode, called the active or donor electrode, is precursor or drug is delivered into the body by electrodiffusion.
The other electrode, called the counter or return electrode, serves to close the electrical circuit through the body. In conjunction with the patient’s skin contacted by the electrodes, the circuit is completed by connection of the electrodes to a source of electrical energy, e.g., a battery. For example, if the ionic substance to be driven into the body is positively charged, then the positive electrode (the anode) will be the active electrode and the negative electrode (the cathode) will serve to complete the circuit. If the ionic substance to be delivered is negatively charged, then the negative electrode will be the active electrode and the positive electrode will be the counter electrode.
Alternatively, both the anode and cathode may be used to deliver drugs of opposite charge into the body. In such a case, both electrodes are considered to be active or donor electrodes. For example, the positive electrode (the anode) can drive a positively charged ionic substance into the body while the negative electrode (the cathode) can drive a negatively charged ionic substance into the body.
It is also known that iontophoretic delivery devices can be used to deliver an uncharged drug or agent into the body. This is accomplished by a process called electro-osmosis. Electro-osmosis is the volume flow of a liquid (e.g., a liquid containing the uncharged drug or agent) through the skin induced by the presence of an electric field imposed across the skin.
Furthermore, existing iontophoresis devices generally require a reservoir or source of the beneficial agent (which is preferably an ionized or ionizable agent or a precursor of such agent) to be iontophoretically delivered into the body. Examples of such reservoirs or sources of ionized or ionizable agents include a pouch as described in the previously mentioned Jacobsen U.S. Patent No. 4,250,878, or a pre—formed gel body as described in Webster U.S.
Patent No. 4,382,529. Such drug reservoirs are electrically connected to the anode or the cathode of an iontophoresis device to provide a fixed or renewable source of one or more desired agents.
There is a continuing need to develop an iontophoretic drug delivery device with improved characteristics and specifically with improved control over the drug delivery profile. Conventional microporous ultrafiltration-type membranes have been used to control the rate at which agent (i.e., drug) is released from a passive transdermal or transmucosal delivery device. Passive delivery devices deliver drug or other beneficial agent through the skin by diffusion. These passive delivery devices are driven by a drug concentration gradient (i e., the concentration of drug in the drug reservoir of the device is greater than the concentration of drug in the skin of the patient). ultrafiltration-type membranes have been suggested for use in while conventional semipermeable iontophoretic delivery devices (e.g., in Parsi U.S.Patent 4,731,049 and Sibalis U.S.Patent 4,460,689) they have been found to be unsuitable for use in portable battery-powered iontophoretic delivery devices because of their high electrical resistivity (i.e., resistivity to ionic transport). Therefore, there is a need for a membrane having low electrical resistivity which may be used to control the rate at which agent is released from an electrically- powered iontophoretic agent delivery device.
There is also a need for a control membrane in an iontophoretic drug delivery device which can substantially prevent passive release of drug from the device when the device is placed on the patient’s body. delivering highly potent drugs which might otherwise become harmful Such a membrane also would have important advantages when to the patient if present at greater than predetermined plasma concentrations. The membrane would prevent too much drug from being delivered, if for example, the delivery device is inadvertently placed on cut or abraded skin or on a body surface which has somehow been compromised. Further, such a membrane would permit safer handling of the device during manufacture and use. ; Such a membrane, by eliminating or at least greatly reducing passive transport, would also allow the drug delivery rate to be substantially reduced when the power to the iontophoretic delivery device is turned off. Thus, the membrane would have particular utility in both iontophoretic delivery devices which are turned on and off by the patient for "on-demand" delivery of a beneficial agent (e.g., an anesthetic or other pain killing agent) or in iontophoretic delivery devices having a control circuit which alternates drug delivery pulses with periods during which no drug is delivered.
Since the membrane would substantially reduce the rate at which beneficial agent is passively delivered from the device, the membrane would allow a more precise patterned drug delivery profile.
Along with the growing interest in the development of iontophoretic delivery devices, there has been a growing need for improved techniques of testing the performance characteristics of the devices. For example, state of the art techniques for measuring the in vitro agent release rates of passive transdermal systems are inadequate for testing the agent release rates of electrically powered iontophoretic delivery devices. Typically, such testing involves placing the passive delivery system on either a section of human cadaver skin or on a synthetic membrane which exhibits passive drug diffusion characteristics similar to that of skin. Examples of such membranes include a copolyester membrane sold by E.I. DuPont de DE under the tradename Hytrel* or an ethylene The other side of the skin or Nemours of Wilmington, vinyl acetate copolymer such as EVA 9.
* Trademark _ 5 _ membrane is in contact with an aqueous receiving medium. The drug is delivered from the passive delivery system through the skin or membrane into the aqueous medium where it can be collected for measurement. Unfortunately, these passive delivery test membranes do not closely approach the electrically—assisted ion transport characteristics of skin and therefore cannot be used to accurately predict the 1 performance characteristics of an iontophoretic delivery device. in addition, cadaver skin exhibits an unacceptably high level of variation (when measuring device stability) and sufficient quantities of cadaver skin are not always readily available. Thus, there is a need for a synthetic membrane which exhibits electrically-assisted ionic transport properties similar to those of skin and which therefore can be used to test the performance characteristics of an iontophoretic agent delivery device in vitro.
DISCLOSURE OF THE INVENTION It is an object of this invention to provide an iontophoretic delivery device or electrode having an improved control membrane or means for controlling the rate at which agent is released.
It is another object of this invention to provide a safety mechanism for an electrically powered iontophoretic delivery device or electrode to ensure that agent is only substantially released during those periods when the power is turned on.
It is a further object of this invention to provide an iontophoretic device or electrode having a membrane or means for controlling the rate at which agent is released which will allow passage of agent at a predetermined rate when the power is turned on and which acts as a barrier to the passage of agent when the power is turned off.
These and other objects are met by devices or electrodes as set forth in the claims.
Preferably, the membrane exhibits a (JEK + Jp)/Jp ratio of at least about 6, a voltage drop across the membrane of less than about 0.1 volts and a Jp of less than about 50 ,ug/hr-cmz.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a cross sectional view of one embodiment of a device for iontophoretic delivery of a beneficial agent, according to the present invention; Figure 2 is a top view of the embodiment shown in Figure 1, with parts shown in phantom.
Figure 3 is a cross sectional view of another embodiment of an iontophoretic delivery device according to the present invention; .
Figure 4 is a perspective view of a single electrode of an iontophoretic agent delivery device, in accordance with the present invention; Figure 5 is a graph comparing the electrically-assisted and passive fluxes of metoclopramide through various membranes in a device of the present invention; and Figure 6 is a graph illustrating the effect of hydrophilic resin loading on the ratio of electrically-assisted flux—to-passive flux for the drug metoclopramide through various membranes in a device of the present invention.
MODES FOR CARRYING OUT THE INVENTION The membrane in the device or electrode of the present invention inhibits the releast of drug due to passive diffusion when the device is positioned on the patient’s body. The flux due to passive diffusion is termed JD. while the delivery of drug due to passive diffusion from an electrically powered iontophoretic delivery device is not usually a problem since the drugs delivered by such devices do not easily penetrate the skin via passive diffusion, if the skin is compromised in some manner, such as by being cut or scraped, a harmfully large dose of drug Could be delivered. The control membrane in the present invention limits the steady state passive diffusion rate (Jp) of agent therethrough to a level below about 100 pg/hr-cmz when the device is positioned on the patient’s body. Preferably the steady state passive diffusion rate (JD) is below about 50 pg/hr-cmz and most preferably below about 10 ug/hr-cmz.
The above limits for the steady state passive diffusion rate should not be exceeded regardless of the concentration gradient of drug or agent across the membrane. In most cases, the concentration of drug in the drug reservoir of the iontophoretic delivery device will be at or near saturation while the concentration of drug in the body surface of the patient will be extremely low. Thus, even at such a maximum concentration gradient, the steady state passive flux of drug should not exceed the above mentioned limits.
In order to determine whether a particular membrane meets the steady state passive diffusion characteristics mentioned above, the following measurement procedure may be used. The membrane is secured between the compartments of a two«compartment cell. One surface of the membrane is exposed to the donor compartment which contains an aqueous solution of the drug to be delivered. The concentration of drug in the donor compartment is 0.1 g/ml. The opposite surface of the membrane is in Contact with the receptor compartment which contains a receptor solution composed of Dulbecco’s phosphate buffered saline (pH 7) sold by Gibco Laboratories of Grand Island, NY, Catalogue No. 310-4040, and having a nominal NaCl concentration of 0.137 M. The solution in the donor compartment is in contact with an electode, which is preferably composed of Ag/AgCl. Similarly, the receptor solution is in contact with an electrode, also preferably composed of Ag/AgCl. The electrodes are connected to opposite poles of a galvanostat capable of providing a constant level of electric current to the two electrodes. JD is measured using this apparatus with the galvanostat providing no electric current to the electrodes. when measuring passive flux, there is always an initial transient period before the passive flux reaches steady state. The term JD used herein refers to the steady state passive flux of drug through the membrane and therefore the flux should be measured at least about an hour after the membrane is exposed to the drug concentration gradient between the donor and receptor solutions in order to be certain the flux has reached a steady state level. when a control membrane useful in this invention is incorporated into an iontophoretic delivery device, the passive release of drug from the device is substantially prevented and therefore the release of drug is predominantly controlled by the magnitude of the electrical current. Therefore, even if the skin is compromised, the amount of drug delivered by the iontophoretic device is controlled to a safe level.
In addition to limiting the passive diffusion of drug, the control membrane in this invention exhibits a substantially higher electrically-assisted flux of drug than the flux of drug due to passive diffusion. The steady state electrically-assisted flux or electrokinetic flux J", is the sum of the fluxes due to electromigration and electro-osmosis. As mentioned above, the flux due to passive diffusion is termed JD. Thus, the total flux (JT) occurring during electrotransport is equal to the sum of the electrically-assisted flux (JEK) and the flux due to passive diffusion (JD). the term J, is used interchangeably with the expression (JEK + JD).
Thus, Jr equals the sum of JEK and JD. Hereinafter, Likewise, the ratio J,/JD is equal to, and is hereinafter used (JEK + JD)/JD.
The control membrane in the present invention has a J,/JD ratio interchangeably with, the ratio of at least about 4, preferably at least about 6, and most preferably at least about 10. Like the steady state passive flux (Jp), the steady state total flux (JT) likewise will be effected by the drug concentration gradient across the membrane. This is so because the total flux (JT) includes the passive flux (JD), which passive flux is effected by the drug concentration gradient across the membrane. The above-mentioned limits for the JT/Jp ratio should be met or exceeded regardless of the drug concentration gradient across the membrane.
In order to determine whether a particular membrane meets the above-mentioned requirements for the JT/Jg ratio, the steady state total flux (J7) may be measured using the same apparatus used to measure JD and described above. However, when measuring JT, the electrodes of the two compartment cell are connected to a galvanostat which supplies a constant electric current of 100 pA/cmz of membrane.
A suitable galvanostat is manufactured by EG&G Princeton Applied Research, Model No. 363. As with the passive flux, the total flux (JT) used herein refers to the steady state total flux and therefore should be measured at least about an hour after the membrane is exposed to the drug concentration gradient between the donor and receptor solutions.
In addition to the JD value and the JT/JD ratio, the control membrane in the present invention should have a sufficiently low voltage drop across the membrane to enable a portable power source, such as a low voltage (i.e., up to about 20 volts) battery, to deliver beneficial agent to the skin or mucosa of a patient. A control membrane for use in an iontophoretic delivery device should exhibit a voltage drop of less than about 1 volt, and preferably less than about 0.1 volts. performance characteristics (e g., agent delivery rate) of an For membranes which are used to test the iontophoretic delivery device in vitro, a low voltage drop is not as critical since for in vitro testing of iontophoretic delivery devices a higher voltage power source can be used without additional inconvenience. For such testing, the membrane should exhibit a voltage drop of less than about 10 volts, preferably less than about 1 volt, and most preferably less than about 0.1 volts. The voltage drop across a membrane is measured by placing the referenc electrodes (e.g., Ag/AgCl electrodes) of a potentiometer (e.g., Dynascan Corp., Model No. 2905) on either side of the membrane while 100 uA of current per square centimeter of membrane is being passed and recording the potential difference.
One embodiment of a control membrane useful 111 the present Most conventional microporous cellulose acetate membranes are unsuitable invention is a specially modified cellulose acetate membrane. for use as a control membrane because they exhibit an unacceptably high voltage drop across the membrane (e.g., greater than 30 volts). However, conventional cellulose acetate resins can be processed in accordance with the following procedure to achieve an acceptable control membrane. The control membrane is made by dissolving in a solvent composed of methylene chloride and methanol (1) about 60 to 95 parts by weight of cellulose acetate resin (e.g., cellulose acetate 398-IO having an acetyl content of 39.8 wt% and a falling ball viscosity of 10 seconds, manufactured by Eastman Kodak Co. of Rochester, NY) and (2) about 5 to 40 parts by weight of a water soluble material having a molecular weight at least as great as the molecular weight of the drug or beneficial agent being iontophoretically delivered. Suitable water soluble materials include polyethylene glycol, non—cross linked polyvinylpyrrolidone, polyvinylalcohol and water soluble starch derivatives such as hydroxypropylmethyl cellulose and hydroxyethyl cellulose. The mixture is solvent cast to form a membrane and the solvent is allowed to evaporate. The membrane is then soaked overnight in water in order to leach out substantially all of the water soluble material.
This leaves a membrane composed substantially entirely of e.g., cellulose acetate and having a pore volume of about 5 to 40%.
A second embodiment of a control membrane useful in the present invention is a composite membrane comprising a mixture of a hydrophobic microporous polymer and a selected amount of a hydrophilic polymer. In addition to the hydrophilic polymer, the composite membrane may optionally contain standard fillers, surfactants to aid in improving the wetting characteristics of the membrane, leachable pore-forming agents, fibers or otherfillers used as reinforcing agents, as well as a loading of the drug or other beneficial agent being delivered by the iontophoretic delivery device. The composite membrane can be manufactured by blending the hydrophobic polymer, the hydrophilic polymer and any fillers using standard techniques and then forming a membrane by solvent casting, melt processing or extrusion of the polymer blend.
The process of blending a hydrophilic resin into a hydrophobic matrix actually enhances the J7/Jp ratio of the membrane. Thicker membranes also exhibit a larger JT/JP ratio since the passive flux decreases for thicker membranes without affecting the electrokinetic flux. However, a higher voltage is required to maintain the electrokinetic flux.
As used herein, the term "hydrophobic polymer" refers to polymers having an equilibrium water content of less than about 10%. Suitable hydrophobic polymeric materials for use in the control membrane useful in the present invention include without limitation, polycarbonates i.e., linear polyesters of carbonic acids in which carbonate groups recur in the polymer chain by phosgenation of a dihydroxy aromatic such as bisphenol A, polyvinylchlorides, polyamides such as polyhexamethylene adipamide and other such polyamides commonly known as "nylon", modacrylic copolymers such as those formed of polyvinylchloride and acrylonitrile, and styrene-acrylic acid copolymers, polysulfones such as those characterized by diphenylene sulfone groups in the linear chain thereof, halogenated polymers such as polyvinylidene fluoride and polyvinylfluoride, polychloroethers and thermoplastic polyethers, acetal polymers such as polyformaldehyde, acrylic resins such as polyacrylonitrile, polymethyl methacrylate and poly n-butyl methacrylate, polyurethanes, polyimides, polybenzimidazoles, polyvinyl acetate, aromatic and aliphatic polyethers, cellulose esters such as cellulose triacetate, epoxy resins, olefins such as polyethylene and polypropylene, porous rubber, poly(ethylene oxides) which are sufficiently cross-linked to have an equilibrium water polyvinylpyrrolidones which are sufficiently cross-linked to have an equilibrium water content of less than about 10%, poly(vinyl alcohols) which are sufficiently cross-linked to have an equilibrium water content of less than about content of less than about 10%, %; derivatives of polystyrene such as poly(sodium styrenesulfonate) and polyvinylbenzyltrimethyl- ammonium chloride, poly(hydroxyethyl methacrylate), poly(isobutyl vinyl ether), polyisoprenes, polyalkenes, ethylene vinyl acetate copolymers, particularly those having 1-40 weight percent vinyl acetate content, such as those described in U.S.Patent No. 4,144,317, polyamides, and polyurethanes. This list is merely exemplary of the materials suited for use in this invention. A more extensive list can be found in J.R. Scott & W.J. Roff, Handbook of Common Polymers (CRC Press, 1971) and in patents disclosing suitable materials for use in manufacturing microporous membranes such as U.S Patent No. 3,797,494.
As used herein, the term "hydrophilic resin" refers to resins which are at least water wetable but not necessarily water soluble and having an equilibrium water content of greater than about 10% and preferably greater than about 20%. Suitable hydrophilic resins for use in the control membrane useful in the present invention include materials such as polyvinylpyrrolidone, polyethylene oxides, polyox, polyox blended with polyacrylic acid or Carbopol*, cellulose * Trademark derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, pectin, starch, guar gum, locust bean gum, and the like, along with blends thereof. Particularly suitable hydrophilic materials are ion exchange resins having a degree of cross-linking providing an equilibrium water content greater than about 10%. Ion exchange resins and their properties are described in The Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Edition, Volume 13, pps. 678 to 705, John Wiley & Sons (1981).
Particularly preferred ion exchange resins have ion exchange functional groups such as sulfonic acid, carboxylic acid, imidodiacetic acid and quaternary amines. These include,9Without limitation, the commercially available cation and anion exchange resins listed in the tables below.
Cation Exchanqe Resins NAME FORM SIZE DRY RESIN BED MOISTURE PORE LBACKBONEI mesh mea/q mea/mL % of total SIZE AG sow-x12* H 100-200 5 2.3 42-48 small (Sulfonic acid) Bio-Rex@70* Na 200-400 10.2 3.3 65-74 large (Carboxylic acid) Chelex®100* Na 100-200 2.9 0.7 71-76 large Chelating resin (Iminodiacetic acid) Amberlite H 20-50 5.0 1.8 49-55 medium IR-l20** (Sulfonic acid) Anion Exchange Resins NAME ‘ FORM SIZE DRY RESIN BED MOISTURE PORE IEACKBONEI mesh meo/o mea/mL % of total SIZE AG I:X8* Cl 20-50 3.2 1.4 39-45 medium (‘MN I Amberlite Cl 20-50 3.3 1.2 42-48 medium IRA-400** (RN(CH3)3) * sold by Bio-Rad of Richmond, CA ** sold by Mallinckrodt of St. Louis, MI This invention has utility in connection with the delivery of drugs within the broad class normally delivered through body surfaces and membranes, including skin, mucosa and nails. As used herein, the expressions "agent" and "drug" are used interchangeably and are intended to have their broadest interpretation as any therapeutically active substance which is delivered to a living organism to produce a desired, usually beneficial, effect.
The device of the present invention can be used to deliver, in a controlled manner, the following drugs: baclofen, betamethasone, beclomethasone, dobutamine, doxazosin, droperidol, fentanyl, sufentanil, lidocaine, methotrexate, micronazole, nicardapine, prazosin, piroxicam, verapamil, tetracaine, diltiazem, indomethacin, ketoprofen, hydrocortisone, metaclopramide, terbutaline and encainide.
It is most preferable to use a water soluble salt of the drug or agent to be delivered.
The invention is best understood with reference to the accompanying drawings. The control membrane useful in this invention can be manufactured as an integral part of an iontophoretic delivery device or electrode, or it can be manufactured separately with adhesive layers or some suitable means for adhering so that it may subsequently be affixed to an iontophoretic delivery device or electrode.
Figure 1 illustrates an embodiment of an electrotransport device 10 utilizing a composite membrane in this invention. Device 10 has two current conducting members, referred to herein as a donor electrode 12 and a counter electrode 14. The electrodes can be metal foils, a polymeric matrix loaded with metal powder, powdered graphite or carbon fibers, or any other electrically conductive material. The donor electrode 12 and the counter electrode 14 are positioned adjacent to the donor electrode pad 16 and the counter electrode pad 18, respectively. In this embodiment, the donor electrode pad 16 contains the agent to be delivered. The pads 16 and 18 can be polymeric matrices or gel matrices, for example, and are separated by an insulator 20 made of a non-conducting polymeric material. Device 10 has a backing layer 22 made of an electrically insulating or non-conductive material such as is commonly used in passive transdermal systems. Electrical power is supplied by power source 24, which can be a battery or a series of batteries, such that the electrode 12 is in electrical contact with one pole of the power _ 15 _ source 24 and electrode 14 is in electrical contact with the opposite pole. The device 10 is adhered to the body surface 26 by means of a peripheral adhesive layer 28. The device 10 normally includes a strippable release liner, not shown, which is removed just prior to application to the body surface.
The control membrane is designated by the numeral 30 and is positioned between the donor electrode pad 16 and the body surface 26, so as to control the rate at which drug is released from the pad 16. In a typical device 10, the donor electrode pad 16 contains an ionizable supply of the drug to be delivered and the counter electrode pad 18 contains a suitable electrolyte. Alternatively, device 10 contains an ionizable supply of drug in both electrode pads 16 and 18 and in that manner both pads 16 and 18 would function as donor electrode pads. For example, positive ions could be introduced into tissues from the anode (positive electrode), while negative ions could be introduced from the cathode (negative pole). membrane 32 In that instance, a second control is positioned between the electrode pad 18 and the body surface 26.
Layer 34 is composed of a non ion-conducting material which acts as a barrier to prevent short-circuiting of the device 10.
Layer 34 can be an air gap, a non-ion conducting adhesive or other suitable barrier to ion flow. Alternatively, membranes 30 and 32 and layer 34 may be comprised of a single continuous membrane having different ion transport properties (i.e., a single membrane having portions 30 and 32 with a low resistance to ionic transport and a portion 34 having a high resistance to ionic transport).
Figure 2 illustrates a top view of the device 10 and shows the parallel alignment of the pads 16 and 18 and the insulator 20. In this configuration, the control membranes 30 and 32 are rectangular in shape. However, the present invention is not limited to any particular electrode shape or configuration. For example, the control membrane could be used in an iontophoretic delivery device having electrodes which are aligned peripherally (i.e., the donor electrode is centrally positioned while the counter electrode surrounds, in spaced-apart relation, the donor _ 17 _ electrode), in a circular configuration for example, and the composite membrane would be shaped accordingly.
The size of the control membranes 30 and 32 can vary with the size of the electrode pads 16 and 18. Generally, the electrode pads will have a combined area within the range of from less than 1 cm2 to greater than 200 cmz, and preferably about 5-50 cmz. Similarly, the composite membrane will typically be within that range.
In general, the control membrane will have a thickness in the range of about 0.025 mm to 0.38 mm (1 to 15 mils), preferably within a range of about 0.076 mm to 0.13 mm (3 to 5 mils).
Figure 3 illustrates another embodiment of an electrically powered iontophoretic delivery device, designated by the numeral 36, and suitable for use with the control membrane 30.
Device 36 has an agent reservoir 38 which can be in the form of a flexible bag as shown or a polymer matrix as in device 10. A first current conducting member 40 is positioned between reservoir 38 and battery 42. A second current conducting member 44 is positioned between battery 42 and a conductive backing member 46. The device 36 has an electrically insulating member 48 and a peripheral ion-conducting adhesive layer 50. The device 36 is packaged with a strippable release liner 52. Suitable materials for use in the layers of device 36, except for the control membrane 30, are disclosed in U.S Patent No. 4,713,050.
Figure 4 illustrates an iontophoresis electrode 54 (i e., a donor electrode) suitable for use with the control membrane 30.
Electrode 54 has a current conducting member 56, an agent reservoir 58 and a control membrane 30. The electrode 54 adheres to the body surface by means of an ion-conducting adhesive layer 60. The electrode 54 has a fastener 62 by which it can be connected to an external power source.
Suitable materials for use in the electrode 54, except for the control membrane 30, are disclosed in U.S.Patent No. 4,274,420. _ 13 _ The control membrane described hereinbefore can also be used for testing the performance characteristics (e.g., drug delivery rate from the iontophoretic delivery device, the amount of agent contained in the device, the magnitude of electrical current flowing through the device, the agent discharge profile as a function of time, and the discharge capacity of the electrical power source, etc.) of an electrically powered iontophoretic delivery device in vitro. This is especially useful for predicting the actual in vivo performance characteristics of the iontophoretic delivery device. it is desirable that the membrane have both passive and electrically~assisted transport characteristics similar to_that of skin. The control membrane For this use, described meets these requirements.
An evaluation of the agent release characteristics of an iontophoretic delivery device using a control membrane involves the placement of the device on the surface of the control membrane. A reservoir of receptor solution is in contact with the opposite surface of the membrane. when the iontophoretic delivery device is placed on the membrane, passive transport (i.e., transport due to passive diffusion through the membrane when the power is turned off) of agent into the receptor solution is inhibited. when the power is turned on, the delivery device transports agent through the control membrane into the receptor solution where it is collected and measured.
Having thus generally described our invention, the following examples will further illustrate selected preferred embodiments.
EXAMPLE I Composite membranes for use in this invention were made using the following materials. Two hydrophobic polymers were used: ethylene vinyl acetate having 28 weight percent vinyl acetate content (EVA 28) and ethylene vinyl acetate having 40 weight percent vinyl acetate content (EVA 40). Three hydrophilic resins were used: (1) polyvinylpyrrolidone (PVP) having an equilibrium water content of about 100%, a wettable resin which picks up a slight positive charge _ 19 _ due to hydrogen ion adsorption at amine sites; (2) Bio—Rex*70, a macroreticular acrylic polymer based carboxylic acid cation exchange resin made by Bio-Rad Laboratories, of Richmond, CA; and (3) Che1ex* 100, a styrene divinylbenzene lattice with paired imidodiacetate cation exchange groups also made by Bio-Rad Laboratories. Two particle sizes of Chelex 100 were used: particles having a size smaller than 400 mesh and particles having a size in the range of 100-200 mesh. All films containing PVP were made with EVA 28 as the hydrophobic matrix material. Membranes containing Bio-Rex 70 and Chelex 100 were made with EVA 40 as the hydrophobic matrix material. Membranes were made by solvent casting or melt All membranes containing PVP were made by standard melt processing techniques and all membranes containing Bio-Rex 70 were solvent cast from methylene chloride and dried at ambient conditions.
Both methods of preparation were used for membranes containing Chelex 100. processing.
The transport properties of these membranes were evaluated by measuring the passive and electrically-assisted flux of metoclopramide (MCP) across each membrane. This was done using a two compartment cell. The membranes were each secured between the donor and receptor compartments of the cell. The donor compartment contained an electrode composed of Ag/Agcl while the receptor compartment contained an electrode also composed of Ag/Agcl. An MCP solution having a concentration of 0.1 g MCP/ml was placed in the donor compartment and the receptor compartment was filled with Dulbecco’s phosphate buffered saline (pH 7). Dulbecco’s phosphate buffered saline (DPBS) has a nominal NaCl concentration of 0.137 M and is sold by Gibco Laboratories of Grand Island, NY, Catalogue No. 310-4040. The experimental temperature for all experiments was 32°C.
Cells operating under passive conditions had zero current applied while cells operating under active or electrically-assisted conditions had 100 uA/cmz of current applied such that positive ions migrated from the donor to the receptor compartment and negative ions migrated from the receptor to the donor compartment. In this manner, the electrode next to the donor solution was the anode and the electrode next to the receptor solution was the cathode. The * Trademark receptor solution was periodically sampled after reaching steady state flux and evaluated for MCP content. At sampling time, all of the receptor solution was removed and replaced with fresh DPBS. The samples were analyzed for MCP content using UV—absorbance at 310 nm.
Electrically-assisted and passive flux profiles of MCP for three volume loadings of Bio—Rex 70 in EVA 40 are shown in Figure 5.
As the Bio-Rex 70 resin loading was increased beyond about 23 vol%, the J,/JD ratio fell below about 3.5. A Bio-Rex'70 resin loading of 33.8 vol% was tested and yielded a JT/JD ratio of only 2, well outside the scope of the present invention. Accordingly, when using Bio—Rex 70 and EVA 40 composite membranes, the Bio-Rex 70,resin loading should be kept below about 23 vol%.
Similarly, when using EVA 28 and PVP composite membranes, the PVP resin loading should be kept below about 12 to 15 vol%.
Table I presents the steady state JT/JP ratios for the membranes tested.
Table I Polymer Resin Resin Loading, vol % V QJLQF Ratio EVA 40 Bio-Rex’70 17.4 7 22.9 3.5 33.8 2 EVA 28 PVP 12 7 4 18 1.9 1.4 34 1.3 EVA 40 Chelex 100 18.5 46 1 17 (100-200 mesh) 24.2 21 i 3 46.4 19 3 3 Membranes incorporating Chele: 100 (particle size of 100-200 mesh) and Chelex 100 (particle size smaller than 400 mesh) exhibit an electrically-assisted steady state flux of about 300 pg/cmzhr.
However, the membranes prepared using the larger (100-200 mesh) _ 21 _ particle size resin exhibit appreciably higher passive flux of MCP.
COMPARATIVE EXAMPLE A Commercial microporous ultrafiltration-type membranes, of the kind disclosed in Parsi U.S.Patent 4,731,049 and Sibalis U 5 Patent 4,460,689, were tested to determine their suitability for use as a control membrane in an iontophoretic drug delivery device. The membranes tested included (Celgard*) polypropylene and polyethylene based microporous membranes manufactured by Hoechst Celanese, of Charlotte, NC; Nuclepore polycarbonate and polyester microporous membranes, manufactured by Nuclepore Corp. of Pleasanton, CA; cellulose acetate membranes mixed with varying amounts of triacetin which was leached out by soaking the membranes overnight in water; and Vycor* porous glass model No. 7930 manufactured by Corning Glass works of Corning, NY, which was cut to various thicknesses. Pore sizes ranged from 40 A for the porous Vycor* to 0.2 pm for Celgard* and were undetermined for the cellulose acetate membranes. The transport properties of the membranes were evaluated as in Example I and are presented in Table II.
* Trademark _ 22 _ Membrane JP J,/Jp Voltage Drop hr-cmz volts Celgard 2400* N/A N/A >30 Celgard 2500* N/A N/A >30 Celgard K 380 >1000 1.0 0,03 Celgard K 381 >1000 1.0 0.09 Celgard K 359 >1000 1.0 0.08 Nuclepore polycarbonate (0.015 p pore size) >1000 1.0 0.15 Nuclepore polycarbonate (0.05 p pore size) >1000 1.0 , 0 1 Nuclepore polycarbonate (0.1 u pore size) >1000 1 0 0.14 Nuclepore polycarbonate (0.4 u pore size) >1000 1.0 0.065 Nuclepore polycarbonate (1.0 u pore size) >1000 1 0 0.18 Nuclepore polyester (0.1 u pore size) >1000 1 0 0.07 Nuclepore polyester (0.4 u pore size) >1000 1 0 0.05 Nuclepore polyester (1.0 u pore size) >1000 1 0 0.07 Cellulose Acetate (20 wt% triacetin) 1 1.0 >30 Cellulose Acetate (30 wt% triacetin) 8 1.0 >30 Cellulose Acetate (40 wt% triacetin) 1.5 1.0 1 3 Vycor (35 mil thickness) 300 2.0 1 5 Vycor (62 mil thickness) 75 1.0 0.3 * The JD and JT/J were not measured For the Celgard 2400 and 2500 membranes due Eb the high measured voltage drop. _ 23 _ None of the commercially available microporous membranes evaluated provided satisfactory results in all three properties of JD, J,/Jp and voltage drop across the membrane. Either the voltage drop across the membrane was too high, as for some of the Celgard* and cellulose acetate membranes, or the passive transport (JD) of MCP greatly outweighed the electrokinetic transport (JEK) (i.e., the membranes had a JT/JD ratio of about 1), thereby making the measured flux with and without applied current indistinguishable.
Likewise, none of the porous cellulose acetate membranes exhibited a JT/Jp ratio greater than 1.0. water soluble leachable triacetin (= 218) was less than the molecular weight of the drug metaclopramide (= 353) COMPARATIVE EXAMPLE 8 Commercial ion exchange membranes, of the type disclosed in Parsi U.S.Patent 4,731,049 and Sanderson U.S.Patent 4,722,726, were tested to determine their suitability for use as a control membrane in an iontophoretic drug delivery device. The membranes tested included both anion and cation exchange membranes. The anion exchange membranes tested were manufactured by RAI Research Corp. of Hauppauge, NY and sold under the tradenames Raipore 1030, Raipore 4030 and Raipore 5030. The cation exchange membranes tested were Nafion* manufactured by E.I.'DuPont de Nemours & Co. of Wilmington, DE; and Raipore 1010, Raipore 4010 and Raipore 5010 manufactured by RAI Research Corp..
The membranes were cut to size and then soaked in a saturated sodium chloride solution. This pretreatment ensured that the co-ion of the membranes fixed charge would be either sodium or chloride.
The transport properties of these materials were measured as in Example I and are presented in Table III.
* Trademark _ 24 _ TabIe III Membrane JD 2 JT/Jp VoItage Drop hr-cm vo1ts Raipore 1030 400 1.0 0.25 Raipore 4030 100 1.3 0.84 Raipore 5030 140 1.1 0.15 Nafion 2.5 1.0 >30 Raipore 1010 1500 1.0 " 0.15 Raipore 4010 180 2.7 0.4 Raipore 5010 2.5 1.9 2 The anion exchange membranes a1T showed no appreciab1e difference in MCP f1ux for either passive or eTectrica1Ty-assisted transport (i e., the membranes exhibited a J,/Jp ratio of about 1.0).
The Nafion* and Raipore SO10 membranes exhibited very sma11 steady state MCP fTuxes. The fTux of MCP through Raipore 1010 indicated that the passive component exceeded the e1ectrokinetic component to a Targe degree (i.e., the membrane exhibited a J,/Jp ratio of about 1) and therefore, both eIectricaTTy-assisted and passive fTuxes were comparab1e.
EXAMPLE II The reTationship between steady state tota1 f1ux (JT) during eTectrica11y assisted transport, the J,/JP ratio and the voltage drop across the membrane was evaTuated for a composite membrane comprised of 18 vo1% CheTex-100 (particTe size sma1Ter than 400 mesh) and 82 voT% EVA 40. TabTe IV shows the range for measured vo1tage drop across the membrane and of the average measured JT vaIues for MCP.
* Trademark _ 25 _ Table IV Current Density Voltage Drop JT gA[cm2 volts gg[cmZ—hr. .14 73 .29 142 .36 276 .90 441 .24 ' 644 .06 948 The magnitude of the passive flux was dependent on the volume fraction of resin within the membrane. However, the electrically-assisted flux was independent of this quantity.
Therefore, the JT/JP ratio can be predicted from the volume fraction of resin and other measurable quantities. This is illustrated in the following example.
EXAMPLE III Twenty composite control membranes were studied. Each of the membranes was composed of a mixture of hydrophobic EVA 40 matrix and one of the following hydrophilic resins: Chelex‘100 (particle size smaller than 400 mesh), Chelex 100 (particle size of 100-200 mesh), Bio-Rex‘70 and PVP. Each of the composite membranes is represented by a data point in Figure 6. The composition for each of the twenty membranes may be determined by measuring the abscissa of each data point, calculating the volume fraction of hydrophilic resin, and then subtracting the volume fraction of hydrophilic resin from 1 to determine the volume fraction of the EVA-40 matrix. The total flux (JT) and the flux due to passive diffusion (Jp) were measured and the JT/JP ratio for each membrane was calculated and plotted against the reciprocal of the volume fraction of hydrophilic resin. are presented in Figure 6.
The results The slopes of the curves presented in Figure 6 were calculated using a linear regression best fit analysis and are presented in Table V. It is possible to compare the slopes directly because all experimental parameters (temperature, donor concentration, current density and membrane thickness) were identical in determining the J,/Jp ratios plotted in Figure 6. Thus, Chelex 100 having a particle size smaller than 400 mesh was the most effective for controlling the passive diffusion of MCP.
Table V Resin Slope Chelex 100 (smaller than 400 mesh) 28.5 Chelex 100 (100-200 mesh) 4.03 — Bio-Rex 70 1.96 PVP 2.87 EXAMPLE IV formed by dissolving 20.0 g of cellulose acetate 398-10 (sold by Eastman Kodak, Co. of Rochester, NY) and 3.53 g polyethylene glycol having a molecular weight of 8000 in 150 ml of a solvent composed of 93% methylene chloride and 7% methanol. The mixture was poured onto a glass plate and spread with a Gardner knife to a thickness of about of the polyethylene glycol had leached out. The leaching left a cellulose acetate membrane having a pore volume of slightly less than %.
The membrane properties JD, JT and voltage drop across the membrane were measured in accordance with the procedures used in Example I. The membrane was found to have the following properties: Jp = 0.95 pg/hr-cmz; J,/JP = 14.2; and Voltage drop across the membrane = 0.5 : 0.2 volts.
Having thus generally described our invention and described in detail certain preferred embodiments thereof, it will be readily apparent that various modifications to the invention may be made by those skilled in the art without departing from the scope of this invention as defined by the following claims.
Claims (8)
1. An iontophoretic agent delivery device for placement on a body surface comprising: a donor electrode including a reservoir containing the agent to be delivered, a counter electrode and a source of electrical power electrically connected to the donor and counter electrodes, the donor and counter electrodes adapted to be placed in spaced apart relationship on the body surface; adhesive means for adhering the device to the body surface in order to maintain the agent reservoir in agent transmitting relation with the body surface; and a membrane interposed between the agent reservoir and the body surface, characterised in that: the agent is selected from baclofen, betamethasone, beclomethasone, dobutamine, doxazosin, droperidol, fentanyl, sufentanil, lidocaine, methotrexate, micronazole, nicardapine, prazosin, piroxicam, verapamil, tetracaine, diltiazem, indomethacin, ketoprofen, hydrocortisone, metaclopramide, terbutaline and encainide; or water soluble salts thereof and (a) the membrane is formed by dissolving in a solvent about 60 to 95 parts by weight of cellulose acetate and 5 to 40 parts by weight of a water soluble material having a molecular weight at least as great as the agent molecular weight, casting the membrane, evaporating the solvent and leaching out substantially all of the water soluble material, whereby the membrane permits electrically-assisted flux (JEK) of the agent therethrough and substantially prevents passive flux (Jp) of the agent therethrough, the membrane exhibiting at a temperature of 32°C a (JEK+-JP)/JP ratio of at least 4 and a voltage drop across the membrane of less than 1 volt both at a current density of 100 uA/cmz, and a Jp of less than 100 pg/hr-cmz or (b) the membrane comprises a mixture of a hydrophilic resin and a hydrophobic polymer, the proportion of hydrophilic resin to hydrophobic polymer being such that the membrane permits electrically—assisted flux (JEK) of the agent therethrough and substantially prevents passive flux (Jp) of the agent therethrough, the membrane exhibiting at a temperature of 32°C a (JEK+Jp)/Jp ratio of at least 4 and a voltage drop across the membrane of less than 1 volt both at a current density of 100 uA/cm2, and a Jp of less than 100 pg/hr-cmz.
2. An iontophoretic agent delivery electrode for placement on a body surface and for delivering an agent selected from baclofen, betamethasone, beclomethasone, dobutamine, doxazosin, droperidol, fentanyl, sufentanil, lidocaine, methotrexate, micronazole, nicardapine, prazosin, piroxicam, verapamil, tetracaine, diltiazem, indomethacin, ketoprofen, hydrocortisone, metaclopramide, terbutaline and encainide; or water soluble salts thereof, through the body surface, comprising: a reservoir containing the agent to be delivered; conductive means for electrically connecting the reservoir to a source of electrical power; adhesive means for maintaining the reservoir in agent transmitting relationship to said body surface; and a membrane interposed between the agent reservoir and the body surface, characterised in that: (a) the membrane is formed by dissolving in a solvent about 60 to 95 parts by weight of cellulose acetate and 5 to 40 parts by weight of a water soluble material having a molecular weight at least as great as the agent molecular weight, casting the membrane, evaporating the solvent and leaching out substantially all of the water soluble material whereby the membrane permits electrically-assisted flux (JEK) of the agent therethrough and substantially prevents passive flux (Jp) of the agent therethrough, the membrane exhibiting at a temperature of 32°C a (JEK+Jp)/JP ratio of at least 4 and a voltage drop across the membrane of less than 1 volt both at a current density of 100 uA/cmz, and a Jp of less than 100 ug/hr—cm2 or (b) the membrane comprises a mixture of a hydrophilic resin and a hydrophobic polymer, the proportion of hydrophilic resin to hydrophobic polymer being such that the membrane permits electrically-assisted flux (JEK) of the agent therethrough and substantially prevents passive flux (Jp) of the agent therethrough, the membrane exhibiting at a temperature of 32°C a (JEK+Jp)/JP ratio of at least 4 and a voltage drop across the membrane of less than 1 volt both at a current density of 100 uA/cm2, and a Jp of less than 100 pg/hr-cmz
3.The device or electrode of claim 1 or claim 2, wherein the hydrophilic resin in b) comprises polyvinylpyrrolidone.
4.The device or electrode of claim 1 or claim 2, wherein said hydrophilic resin in b) comprises an ion exchange resin. 20 _ 31 _
5. The device or electrode of claim 1 or claim 2, wherein said hydrophobic polymer in b) comprises an ethylene vinyl acetate copolymer having a vinyl acetate content in the range of about 1 to 40 weight percent.
6. The device or electrode of claim 1 or claim 2, wherein the agent comprises fentanyl or a water-soluble salt thereof.
7. The device or electrode of claim 1 or claim 2, wherein the agent comprises sufentanil or a water-soluble salt thereof.
8. An iontophoretic agent delivery device as claimed in claim 1, substantially in accordance with either of the embodiments herein described with reference to and/or as shown in
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USUNITEDSTATESOFAMERICA03/10/19882 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE19990566A1 IE19990566A1 (en) | 1990-04-03 |
IE83794B1 true IE83794B1 (en) | 2005-02-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0931564B1 (en) | Electrotransport drug delivery | |
US5232438A (en) | Membrane for electrotransport transdermal drug delivery | |
US5147296A (en) | Membrane for electrotransport transdermal drug delivery | |
EP0596036B1 (en) | Transdermal delivery device | |
US5084006A (en) | Iontopheretic delivery device | |
US5464387A (en) | Transdermal delivery device | |
CA2356197C (en) | Thin polymer film drug reservoirs | |
US20030088205A1 (en) | Electrotransport delivery of leuprolide | |
EP0457849B1 (en) | Electrotransport adhesive | |
IE83794B1 (en) | Electrotransport drug delivery | |
IE19990566A1 (en) | Electrotransport drug delivery | |
KR0154970B1 (en) | Device and method of iontophoretic drug delivery |